While the FDA avoids providing an explicit number, analysis of previously approved drugs in this indication reveals a clear benchmark. A complete response (CR) rate of "about two-thirds" in the pivotal trial is the unofficial target companies like enGene must hit to be considered in the approvable range.
The DDX platform uses a proprietary sugar to deliver large genetic payloads, unlike size-constrained viral vectors. This non-viral approach avoids immunogenicity, allowing for redosing, and relies on simple, available ingredients, which significantly simplifies manufacturing and lowers cost of goods.
Due to high unmet medical need in non-muscle invasive bladder cancer, the FDA created a special regulatory pathway. This guidance allows for full marketing approval based on a single-arm, open-label study of just 100 patients, dramatically accelerating the timeline and reducing the cost to bring new therapies to market.